Idexx Laboratories (IDXX) AI Stock Analysis

• Market Cap: $58.21B
• Dividend Yield: N/A
• Average Volume (3M): 590.08K
• Price to Earnings (P/E): 57.8
• Beta (1Y): 0.90
• Revenue Growth: 8.39%
• EPS Growth: 21.44%
• Country: US
• Employees: 11,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 3.40
• Shares Outstanding: 79,851,330
• 10 Day Avg. Volume: 643,172
• 30 Day Avg. Volume: 590,080
• PEG Ratio: 6.51
• Price to Book (P/B): 21.37
• Price to Sales (P/S): 8.75
• P/FCF Ratio: 42.72
• Enterprise Value/Market Cap: 0.90
• Enterprise Value/Revenue: 12.59
• Enterprise Value/Gross Profit: 20.39
• Enterprise Value/Ebitda: 36.12
• 1Y Price Target: $785.63
• Price Target Upside: 8.22% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 9
• EPS Forecast (FY): 12.9
• Revenue Forecast (FY): $4.29B

• Rating: 75 Outperform
• Price Target: $819.00 ▲(12.82% Upside)

Idexx Laboratories' strong financial performance and positive technical indicators are the primary drivers of its stock score. The company's robust revenue growth and profitability, along with a bullish technical trend, support a favorable outlook. However, the high valuation and absence of a dividend yield present potential risks. The earnings call further reinforces confidence in the company's growth trajectory, though it is not factored into the weighted score due to the methodology.

Positive Factors

Revenue Growth

Strong revenue growth, particularly in CAG Diagnostics, indicates robust demand and effective market penetration, supporting long-term expansion.

Innovation Strategy

Continued innovation in diagnostic instruments like InVue Dx enhances competitive advantage and market leadership, fostering sustainable growth.

Improved Operating Margins

Improved operating margins reflect efficient cost management and profitability, enhancing financial health and investment capacity.

Negative Factors

Decline in U.S. Clinical Visits

A decline in U.S. clinical visits suggests potential headwinds in domestic market demand, which could impact future revenue growth.

Wellness Visits Decline

Decreased wellness visits indicate reduced consumer spending in preventive care, potentially affecting recurring revenue streams.

Foreign Exchange Impact

Foreign exchange impacts can erode profitability, posing a risk to international revenue contributions and financial performance.

Idexx Laboratories Business Overview & Revenue Model

Company Description

IDEXX Laboratories, Inc. is a global leader in veterinary diagnostics and water testing solutions. Founded in 1983 and headquartered in Westbrook, Maine, the company specializes in providing innovative products and services for the veterinary market, including diagnostic tests, instruments, and software solutions. IDEXX also offers products for livestock and poultry health, as well as testing services for drinking water and environmental samples. The company operates primarily in the animal health sector, contributing significantly to its growth and market presence.

How the Company Makes Money

IDEXX Laboratories generates revenue primarily through the sale of diagnostic products and services for veterinarians, which include a wide range of tests for various diseases, instruments for performing those tests, and software solutions that enhance practice management. Key revenue streams include sales of in-house diagnostic instruments and consumables, reference laboratory services, and point-of-care testing products. Additionally, IDEXX earns income from its water testing segment, which provides testing products and services essential for ensuring safe drinking water. The company benefits from a robust network of partnerships with veterinary clinics, laboratories, and research institutions, enhancing its market reach and solidifying its position as a trusted supplier in the veterinary and environmental sectors.

Idexx Laboratories Financial Statement Overview

Summary

Idexx Laboratories exhibits a strong financial profile with consistent revenue and profit growth, efficient cost management, and robust cash flow generation. The balance sheet reflects a balanced approach to leverage, supporting long-term stability. While the company shows slight fluctuations in growth rates, its overall financial health remains solid.

Income Statement

Idexx Laboratories demonstrates strong financial performance with consistent revenue growth and robust profit margins. The TTM data shows a Gross Profit Margin of 61.54% and a Net Profit Margin of 24.41%, indicating efficient cost management and profitability. The EBIT and EBITDA margins are also healthy, reflecting strong operational efficiency. The revenue growth rate of 3.21% in the TTM period suggests steady growth, although slightly lower than previous years.

Balance Sheet

The balance sheet shows a moderate Debt-to-Equity Ratio of 0.85 in the TTM period, indicating a balanced approach to leverage. The Return on Equity is impressive at 64.42%, showcasing strong profitability relative to shareholder equity. However, the Equity Ratio of 46.10% suggests a moderate reliance on debt financing. Overall, the company maintains a stable financial position with effective use of equity.

Cash Flow

Cash flow analysis reveals a strong Free Cash Flow Growth Rate of 23.15% in the TTM period, indicating effective cash generation. The Operating Cash Flow to Net Income Ratio of 1.06 and Free Cash Flow to Net Income Ratio of 0.85 reflect efficient cash conversion from earnings. The company demonstrates solid cash flow management, supporting its operational and strategic initiatives.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.17B	3.90B	3.66B	3.37B	3.22B	2.71B
Gross Profit	2.57B	2.38B	2.19B	2.00B	1.89B	1.57B
EBITDA	1.45B	1.28B	1.22B	1.01B	1.04B	793.81M
Net Income	1.03B	887.87M	845.04M	679.09M	744.85M	581.78M
Balance Sheet
Total Assets	3.39B	3.29B	3.26B	2.75B	2.44B	2.29B
Cash, Cash Equivalents and Short-Term Investments	208.17M	288.27M	453.93M	112.55M	144.45M	383.93M
Total Debt	1.11B	986.95M	1.07B	1.47B	1.03B	1.00B
Total Liabilities	1.83B	1.70B	1.78B	2.14B	1.75B	1.66B
Stockholders Equity	1.56B	1.60B	1.48B	608.74M	689.99M	632.09M
Cash Flow
Free Cash Flow	953.57M	798.08M	772.88M	394.15M	636.00M	540.44M
Operating Cash Flow	1.09B	929.00M	906.51M	542.98M	755.55M	648.06M
Investing Cash Flow	-147.95M	-207.06M	-125.25M	-195.35M	-292.97M	-109.38M
Financing Cash Flow	-1.04B	-878.07M	-442.00M	-370.94M	-697.41M	-248.42M

Idexx Laboratories Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 725.93
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IDXX, the sentiment is Positive. The current price of 725.93 is above the 20-day moving average (MA) of 716.81, above the 50-day MA of 669.73, and above the 200-day MA of 556.73, indicating a bullish trend. The MACD of 19.90 indicates Positive momentum. The RSI at 56.60 is Neutral, neither overbought nor oversold. The STOCH value of 56.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IDXX.

Idexx Laboratories Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
A	79 Outperform	$42.19B	32.56	20.62%	0.68%	6.73%	3.34%
IDXX	75 Outperform	$58.21B	57.79	64.63%	―	8.39%	21.44%
ZTS	74 Outperform	$56.08B	21.44	49.87%	1.63%	2.68%	11.51%
ILMN	73 Outperform	$19.67B	28.84	31.20%	―	-2.39%	―
ELAN	69 Neutral	$11.17B	308.50	0.54%	―	3.08%	-82.39%
RVTY	67 Neutral	$11.65B	51.37	3.04%	0.29%	3.37%	-18.80%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Idexx Laboratories Corporate Events

IDEXX Laboratories Reports Strong Q3 2025 Results

IDEXX Laboratories, Inc., a global leader in pet healthcare innovation, provides diagnostic and software products and services to support veterinary medicine and ensure the safety of milk and water worldwide. Headquartered in Maine, IDEXX employs approximately 11,000 people and serves customers in over 175 countries.

IDEXX Laboratories Appoints Karen Peacock to Board

On October 6, 2025, IDEXX Laboratories elected Karen Peacock as an independent Class I Director and appointed her to its Compensation and Talent Committee and Finance Committee. This strategic addition to the board is expected to enhance the company’s leadership with Peacock’s extensive experience in B2B, SaaS software, and AI, potentially strengthening IDEXX’s position in the pet healthcare industry.

The most recent analyst rating on (IDXX) stock is a Buy with a $745.00 price target. To see the full list of analyst forecasts on Idexx Laboratories stock, see the IDXX Stock Forecast page.

IDEXX Laboratories’ Earnings Call Highlights Strong Growth

IDEXX Laboratories’ recent earnings call reflected a strong quarter characterized by significant revenue and profit growth, primarily driven by robust international performance and record instrument placements. Despite challenges in the U.S. market, such as declining clinical visits and pressure on rapid assay revenues, the company remains optimistic about its innovation-driven strategy. This confidence is underscored by an increase in full-year guidance, indicating a positive outlook despite ongoing macroeconomic challenges.

IDEXX Laboratories Reports Strong Q2 2025 Results

IDEXX Laboratories, Inc. is a global leader in pet healthcare innovation, providing diagnostic and software products and services to the veterinary industry, as well as ensuring the safety of milk and water worldwide. In its latest earnings report, IDEXX Laboratories announced robust financial results for the second quarter of 2025, with a reported revenue growth of 11% and organic growth of 9%, driven by strong performance in its Companion Animal Group (CAG) and Water segments. The company achieved a significant increase in earnings per share (EPS), reporting $3.63, a 49% increase from the previous year, bolstered by strategic innovations and strong commercial execution. Key highlights include a 66% increase in CAG Diagnostics capital instrument revenues and a 15% growth in IDEXX VetLab consumables. The company also updated its 2025 revenue guidance, projecting a range of $4,205 million to $4,280 million, reflecting positive foreign exchange impacts and strong recurring revenue performance. Looking ahead, IDEXX Laboratories remains optimistic about its growth prospects, with an updated EPS outlook for 2025 and continued focus on innovation and expanding its diagnostic solutions globally.